Back to all studies
CompletedNCT00391222

Risperidone Long-acting Injectable (LAI) for Bipolarity

This study is completed in China, in Colombia, in Germany, .... It is testing Risperidone Long-acting Injectable (LAI) for Bipolarity.

BipolarityDrugFrom 18 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What is this study testing?

This study is testing whether Risperidone may be useful for adults experiencing bipolarity.

What would participation involve?

Participants may receive Risperidone, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in China, in Colombia, and in Germany.

Who is it mainly for?

This study appears to be mainly for adults with bipolarity.

What should you check before joining?

Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)
  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateNovember 2006
Recruitment status
Completed
Enrollment listed in the registry
585
Sponsor
Janssen Pharmaceutica N.V., Belgium
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
China, Colombia, Germany, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00391222
Official title
A Randomized, Double Blind, Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Risperidone Long-acting Injectable (LAI) for the Prevention of Mood Episodes in the Treatment of Subjects With Bipolar I Disorder

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

China · 7 sites
  • Baoding
    Baoding
    Site status: Not listed — confirm with the team
  • Beijing
    Beijing
    Site status: Not listed — confirm with the team
  • Guangzhou
    Guangzhou
    Site status: Not listed — confirm with the team
  • Nanjing
    Nanjing
    Site status: Not listed — confirm with the team
  • Shanghai
    Shanghai
    Site status: Not listed — confirm with the team
  • Suozhou
    Suozhou
    Site status: Not listed — confirm with the team
  • Wuhan
    Wuhan
    Site status: Not listed — confirm with the team
Colombia · 6 sites
  • Barranquilla Atlantico
    Barranquilla Atlantico
    Site status: Not listed — confirm with the team
  • Bello Antioquia
    Bello Antioquia
    Site status: Not listed — confirm with the team
  • Bogotá
    Bogotá
    Site status: Not listed — confirm with the team
  • Bogotá S/N
    Bogotá S/N
    Site status: Not listed — confirm with the team
  • Medellin Antioquia
    Medellin Antioquia
    Site status: Not listed — confirm with the team
  • Pereira Risaralda
    Pereira Risaralda
    Site status: Not listed — confirm with the team
Germany · 3 sites
  • Freiburg im Breisgau
    Freiburg im Breisgau
    Site status: Not listed — confirm with the team
  • Hildesheim
    Hildesheim
    Site status: Not listed — confirm with the team
  • Oranienburg
    Oranienburg
    Site status: Not listed — confirm with the team
Greece · 1 site
  • Athens
    Athens
    Site status: Not listed — confirm with the team
India · 10 sites
  • Ahmedabad
    Ahmedabad
    Site status: Not listed — confirm with the team
  • Bangalore
    Bangalore
    Site status: Not listed — confirm with the team
  • Chennai
    Chennai
    Site status: Not listed — confirm with the team
  • Hyderabad
    Hyderabad
    Site status: Not listed — confirm with the team
  • Ludhiana
    Ludhiana
    Site status: Not listed — confirm with the team
  • Mangalore
    Mangalore
    Site status: Not listed — confirm with the team
  • Mumbai
    Mumbai
    Site status: Not listed — confirm with the team
  • New Delhi
    New Delhi
    Site status: Not listed — confirm with the team
  • Pune
    Pune
    Site status: Not listed — confirm with the team
  • Varanasi
    Varanasi
    Site status: Not listed — confirm with the team
Indonesia · 1 site
  • Jakarta
    Jakarta
    Site status: Not listed — confirm with the team
Jordan · 1 site
  • Amman
    Amman
    Site status: Not listed — confirm with the team
Lebanon · 1 site
  • Beirut
    Beirut
    Site status: Not listed — confirm with the team
Malaysia · 2 sites
  • Johor Bahru
    Johor Bahru
    Site status: Not listed — confirm with the team
  • Kuala Lumpur
    Kuala Lumpur
    Site status: Not listed — confirm with the team
Mexico · 7 sites
  • Mexico City
    Mexico City
    Site status: Not listed — confirm with the team
  • Mérida
    Mérida
    Site status: Not listed — confirm with the team
  • Monterrey
    Monterrey
    Site status: Not listed — confirm with the team
  • Puebla City
    Puebla City
    Site status: Not listed — confirm with the team
  • Tabasco
    Tabasco
    Site status: Not listed — confirm with the team
  • Tampico
    Tampico
    Site status: Not listed — confirm with the team
  • Zapopan
    Zapopan
    Site status: Not listed — confirm with the team
Peru · 2 sites
  • Lima
    Lima
    Site status: Not listed — confirm with the team
  • Lima Lima
    Lima Lima
    Site status: Not listed — confirm with the team
Philippines · 3 sites
  • Iloilo City
    Iloilo City
    Site status: Not listed — confirm with the team
  • Mandaluyong
    Mandaluyong
    Site status: Not listed — confirm with the team
  • Mandaue City
    Mandaue City
    Site status: Not listed — confirm with the team
Russia · 13 sites
  • Arkhangelsky District
    Arkhangelsky District
    Site status: Not listed — confirm with the team
  • Chelyabinsk
    Chelyabinsk
    Site status: Not listed — confirm with the team
  • Izhevsk
    Izhevsk
    Site status: Not listed — confirm with the team
  • Kazan’
    Kazan’
    Site status: Not listed — confirm with the team
  • Moscow
    Moscow
    Site status: Not listed — confirm with the team
  • Moscow Region
    Moscow Region
    Site status: Not listed — confirm with the team
  • Nizny Novgorod
    Nizny Novgorod
    Site status: Not listed — confirm with the team
  • Orenburg
    Orenburg
    Site status: Not listed — confirm with the team
  • Saint Petersburg
    Saint Petersburg
    Site status: Not listed — confirm with the team
  • Saratov
    Saratov
    Site status: Not listed — confirm with the team
  • Stavropol Na
    Stavropol Na
    Site status: Not listed — confirm with the team
  • Tomsk Na
    Tomsk Na
    Site status: Not listed — confirm with the team
  • Voronezh
    Voronezh
    Site status: Not listed — confirm with the team
South Africa · 4 sites
  • Bloemfontein
    Bloemfontein
    Site status: Not listed — confirm with the team
  • Cape Town
    Cape Town
    Site status: Not listed — confirm with the team
  • Durban
    Durban
    Site status: Not listed — confirm with the team
  • Pretoria
    Pretoria
    Site status: Not listed — confirm with the team
Taiwan · 2 sites
  • Tainan
    Tainan
    Site status: Not listed — confirm with the team
  • Taipei
    Taipei
    Site status: Not listed — confirm with the team

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: NCT00391222. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study involving Olanzapine, Placebo, Risperidone Long Acting Injectable (LAI). Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.

Who might this study be for?

This study may concern people with bipolarity; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What side effects, interactions, or treatment changes should I check?

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Janssen Pharmaceutica N.V., Belgium, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me